Lung Diseases Research (93.838)
Lung Diseases Research (Assistance Listing 93.838) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $8.7 million in 5 grants from fiscal 2021 to 2025, about $1.7 million per award on average. 80 funding opportunities are open or forecast now.
The typical award was $355,699. Half of the 5 awards fell between $350,272 and $2.7 million, and they ranged from $322,263 to $5.4 million.
- Awarded, FY 2021 to 2025$8.7 million
- Grant awards5
- Typical award$355,699
- Awarded in FY 2025-$250,767
- Size rank1,525 of 1,823
- Type of assistanceProject grants
Key findings
- It is the 1525th largest of 1,823 federal grant programs by five-year awards.
- The 5 largest recipients received 105% of the money.
- Awards went to recipients in 4 states and territories.
What the program funds
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The Division of Lung Diseases supports research and research training on the causes, diagnosis, prevention, and treatment of lung diseases and sleep disorders. Research is funded through investigator-initiated and Institute-initiated grant programs and through contract programs in areas including asthma, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, cystic fibrosis, respiratory neurobiology, sleep and circadian biology, sleep-disordered breathing, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunologic and fibrotic pulmonary disease, rare lung disorders, pulmonary vascular disease, and pulmonary complications of AIDS and tuberculosis. The Division is responsible for monitoring the latest research developments in the extramural scientific community as well as identifying research gaps and needs, obtaining advice from experts in the field, and implementing programs to address new opportunities. Small Business Innovation Research (SBIR) program: To stimulate technological innovation; use small business to meet Federal research and development needs; foster and encourage participation in innovation and entrepreneurship by socially and economically disadvantaged persons; and increase private-sector commercialization of innovations derived from Federal research and development funding. Small Business Technology Transfer (STTR) program: To stimulate technological innovation; foster technology transfer through cooperative R&D between small businesses and research institutions, and increase private sector commercialization of innovations derived from federal R&D.
Open and forecast opportunities
- Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
- Emerging Global Leader Award (K43 Independent Clinical Trial Required)
- NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
- NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
- Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
- NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed)
- NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
- NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
- Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed)
- Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Required)
- Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)
- Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)
- Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
- NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)
- NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)
- Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required)
- Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed)
- Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required)
- Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
Rules from the program listing
Who can apply
Any nonprofit organization engaged in biomedical research and institutions or companies organized for profit may apply for almost any kind of grant. Only domestic, non-profit, private or public institutions may apply for NRSA Institutional Research Training Grants. An individual may apply for an NRSA or, in some cases, for a research grant if adequate facilities to perform the research are available. SBIR grants can be awarded only to United States small business concerns (entities that are independently owned and operated for profit or owned by another small business that itself is independently owned and operated for profit, or owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these and have no more than 500 employees including affiliates). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. or its possessions except under rare and unique circumstances where foreign components are thoroughly justified and necessary to the overall completion of the project. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council.
What the money can and cannot pay for
Grants may support stipends, research expenses, supplies, travel, and research training tuition as required to perform the research effort. Restrictions or limitations are imposed against the use of funds for entertainment, foreign travel, general-purpose equipment, alterations and renovations, and other items not regularly required for the performance of research. Individual predoctoral and postdoctoral national research service awards (NRSAs) are made directly to individuals through their universities for research training in heart and vascular diseases. NRSA awards may be made to eligible institutions to enable them to appoint individuals selected by the institution for research training. Certain service and payback provisions may apply to postdoctoral individuals upon termination of the award or termination of the appointment. SBIR Phase I awards (of approximately 6 to 24 months in duration) are to establish the scientific and technical merit of the proposed research effort, and feasibility of ideas that appear to have commercial potential. Direct to Phase II SBIR awards are for projects that have been developed beyond the feasibility phase using resources other than NIH Phase I awards that meet program needs and exhibit potential for commercial application. SBIR Phase IIB awards are for promising projects that require additional time and funding to advance to commercialization as well as ultimate approval or clearance by a Federal regulatory agency .
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Deadlines
Contact the headquarters or regional location, as appropriate for application deadlines
Award range and average, in the agency's words
Grants: 4,480 to $4,545,822; $542,589. SBIR Phase I-- $294,551, Phase II- $931,788; STTR Phase I- $265,043, Phase II- $872,004.
Funding history and past recipients
From fiscal 2021 to 2025, Lung Diseases Research (93.838) awarded $8.7 million across 5 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 1 | $5.4 million |
| New England Research Institutes Inc | Massachusetts | 1 | $2.7 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 1 | $355,699 |
| University of Washington | Washington | 1 | $350,272 |
| The Trustees of Columbia University in the City of New York | New York | 1 | $319,659 |
Who usually wins
Nonprofits received 59% of the money, businesses 30% and colleges and universities 11%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Nonprofits | 1 | $5.1 million | 59% |
| Businesses | 1 | $2.7 million | 30% |
| Colleges and universities | 3 | $981,562 | 11% |
By state
1 state has a page for this program: those that received at least $1 million or 10 awards. It is Massachusetts.
| State | Awards | Amount |
|---|---|---|
| Massachusetts | 2 | $7.8 million |
| Washington | 1 | $350,272 |
| New York | 1 | $319,659 |
| Pennsylvania | 1 | $300,836 |